Mediators of the Age Effect in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)
Authors:
- Jenifer H. VoeksJVJenifer H. Voeks
- George HowardGHGeorge Howard
- Gary RoubinGRGary Roubin
- Richard FarbRFRichard Farb
- Donald HeckDHDonald Heck
- William LoganWLWilliam Logan
- Mary LongbottomMLMary Longbottom
- Alice SheffetASAlice Sheffet
- James F. MeschiaJMJames F. Meschia
- Thomas G. BrottTBThomas G. Brott
- 1 October 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 46 (10) , 2868-2873
Abstract
Background and Purpose—: There is higher combined risk of stroke or death (S+D) at older ages with carotid stenting. We assess whether this can be attributed to patient or arterial characteristics that are in the pathway between older age and higher risk. Methods—: Mediation analysis of selected patient (hypertension, diabetes mellitus, and dyslipidemia) and arterial characteristics assessed at the clinical sites and the core laboratory (plaque length, eccentric plaque, ulcerated plaque, percent stenosis, peak systolic velocity, and location) was performed in 1123 carotid artery stenting–treated patients in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). We assessed the association of age with these characteristics, the association of these characteristics with stroke risk, and the amount of mediation of the association of age on the combined risk of periprocedural S+D with adjustment for these factors. Results—: Only plaque length as measured at the sites increased with age, was associated with increased S+D risk and significantly mediated the association of age on S+D risk. However, adjustment for plaque length attenuated the increased risk per 10 years of age from 1.72 (95% confidence interval, 1.26–2.37) to 1.66 (95% confidence interval, 1.20–2.29), accounting for only 8% of the increased risk. Conclusions—: Plaque length seems to be in the pathway between older age and higher risk of S+D among carotid artery stenting–treated patients, but it mediated only 8% of the age effect excess risk of carotid artery stenting in CREST. Other factors and mechanisms underlying the age effect need to be identified as plaque length will not identify elderly patients for whom stenting is safe relative to endarterectomy. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00004732.Keywords
This publication has 18 references indexed in Scilit:
- Detection of Symptomatic Carotid Plaque Using Source Data from MR and CT Angiography: A Correlative StudyCerebrovascular Diseases, 2015
- Effect of white-matter lesions on the risk of periprocedural stroke after carotid artery stenting versus endarterectomy in the International Carotid Stenting Study (ICSS): a prespecified analysis of data from a randomised trialThe Lancet Neurology, 2013
- Length of Carotid Stenosis Predicts Peri-Procedural Stroke or Death and Restenosis in Patients Randomized to Endovascular Treatment or EndarterectomyInternational Journal of Stroke, 2013
- Age and Outcomes After Carotid Stenting and EndarterectomyStroke, 2011
- Age Modifies the Relative Risk of Stenting versus Endarterectomy for Symptomatic Carotid Stenosis – A Pooled Analysis of EVA-3S, SPACE and ICSSEuropean Journal of Vascular and Endovascular Surgery, 2011
- Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient dataThe Lancet, 2010
- Design of the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST)International Journal of Stroke, 2010
- Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trialThe Lancet Neurology, 2008
- Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE studyThe Lancet Neurology, 2008
- North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress.Stroke, 1991